The Journal of Immunology, Vol 156, Issue 5 2009-2013, Copyright © 1996 by American Association of Immunologists

ARTICLES

Epitope mapping of C1 inhibitor autoantibodies from patients with acquired C1 inhibitor deficiency

S He, S Tsang, J North, N Chohan, RB Sim and K Whaley
Department of Microbiology and Immunology, University of Leicester, UK.

We report six patients with acquired C1 inhibitor (C1-inh) deficiency associated with serum C1-inh autoantibodies and circulating cleaved (96 kDa), functionally inactive C1-inh. In three patients, all of whom had IgG-kappa paraproteins in their sera, the Abs were IgG-kappa. In the remaining three patients, the Abs were IgM (2 kappa, 1 lambda). These data suggest that all the Abs were monoclonal. The autoantibodies recognized two synthetic peptides (peptides 2 and 3), which spanned the reactive center of C1-inh. Binding to peptide 3 (residues 448-459) was greater than to peptide 2 (residues 438-449), suggesting that the epitope recognized by the autoantibodies was expressed principally by peptide 3. Both peptides inhibited the binding of the autoantibodies to C1-inh. None of the autoantibodies recognized peptide 1 (residues 428- 440), and this peptide did not inhibit the binding of the autoantibodies to C1-inh. The use of substituted peptides suggested that residues Q452 and Q453 made significant contributions to the epitope, and computer modeling studies showed their side chains to be surface exposed in the intact molecule. However, computer modeling also showed that none of the side chains of the polar residues in peptide 2 were sufficiently close to Q452 and Q453 to be able to contribute to a shared epitope. As peptide 2 could inhibit the binding of C1-inh autoantibodies to peptide 3 and vice versa, we conclude that an autoepitope also exists in peptide 2. Computer modeling and the use of substituted peptides suggested that the sequence LLVF (residues 446- 449) in peptide 2 is structurally similar to the sequence QQPF (residues 452-455) in peptide 3. We therefore conclude that there are two potential epitopes in the intact C1-inh molecule that are capable of binding to C1-inh autoantibodies.

This article has been cited by other articles:

				S. Schmidt, T. Schneider, I. Schmidt-Wolf, Y. Ko, U. Schlegel, T. Klockgether, and H.-J. Hertfelder Letter to the editor Multiple Sclerosis, April 1, 2004; 10(2): 243 - 244. [PDF]

				R. Zahedi, R. C. MacFarlane, J. J. Wisnieski, and A. E. Davis III C1 Inhibitor: Analysis of the Role of Amino Acid Residues Within the Reactive Center Loop in Target Protease Recognition J. Immunol., August 1, 2001; 167(3): 1500 - 1506. [Abstract] [Full Text] [PDF]

				J. Hauert, P. A. Patston, and M. Schapira C1 Inhibitor Cross-linking by Tissue Transglutaminase J. Biol. Chem., May 5, 2000; 275(19): 14558 - 14562. [Abstract] [Full Text] [PDF]

				G. Niederwieser, S. Schmidt, and U. Schlegel Lethal capillary leak syndrome after a single administration of interferon beta-1b Neurology, April 11, 2000; 54(7): 1542 - 1546. [Full Text] [PDF]

				S. Schmidt, H.-J. Hertfelder, T. von Spiegel, R. Hering, M. Harzheim, H. Lassmann, M. Deckert-Schluter, and U. Schlegel Lethal capillary leak syndrome after a single administration of interferon beta-1b Neurology, July 1, 1999; 53(1): 220 - 220. [Abstract] [Full Text]